Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
Stroke. 2010 Feb;41(2):295-9. doi: 10.1161/STROKEAHA.109.562827. Epub 2010 Jan 7.
In ischemic stroke, the site of arterial obstruction has been shown to influence recanalization and clinical outcomes. However, this has not been studied in randomized controlled trials, nor has the impact of arterial obstruction site on reperfusion and infarct growth been assessed. We studied the influence of site and degree of arterial obstruction patients enrolled in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).
EPITHET was a prospective, randomized, placebo-controlled trial of intravenous tissue plasminogen activator (tPA) in the 3- to 6-hour time window. Arterial obstruction site and degree were rated on magnetic resonance angiography blinded to treatment allocation and outcomes.
In 101 EPITHET patients, 87 had adequate quality magnetic resonance angiography, of whom 54 had baseline arterial obstruction. Infarct growth attenuation was greater in those with tPA treatment compared to placebo among patients with middle cerebral artery (MCA) obstruction (P=0.037). The treatment benefit of tPA over placebo in attenuating infarct growth was greater for MCA than internal carotid artery (ICA) obstruction (P=0.060). With tPA treatment, good clinical outcome was more likely with MCA than with ICA obstruction (P=0.005). Most patients with ICA obstruction did not achieve good clinical outcome, whether treated with tPA (100%) or placebo (77%). The study was underpowered to prove any treatment benefit of tPA among patients with any or severe degree of arterial obstruction.
Arterial obstruction site strongly predicts outcomes. ICA obstruction carries a uniformly poor prognosis, whereas good outcomes with MCA obstruction are associated with tPA therapy.
在缺血性脑卒中患者中,动脉阻塞部位已被证实会影响再通和临床结局。但该结论尚未在随机对照试验中得到验证,动脉阻塞部位对再灌注和梗死体积的影响也尚未得到评估。我们研究了入选 Echoplanar Imaging Thrombolytic Evaluation Trial(EPITHET)的患者的动脉阻塞部位和程度的影响。
EPITHET 是一项前瞻性、随机、安慰剂对照试验,旨在评估 3-6 小时时间窗内静脉注射组织型纤溶酶原激活剂(tPA)的效果。动脉阻塞部位和程度在磁共振血管造影(MRA)上进行评估,评估时对治疗分配和结局设盲。
在 101 名 EPITHET 患者中,87 名患者的 MRA 质量足够,其中 54 名患者存在基线动脉阻塞。与安慰剂相比,tPA 治疗可使大脑中动脉(MCA)阻塞患者的梗死体积衰减更大(P=0.037)。与颈内动脉(ICA)阻塞相比,tPA 治疗使 MCA 阻塞患者梗死体积衰减的获益更大(P=0.060)。接受 tPA 治疗的患者中,MCA 阻塞患者的临床结局优于 ICA 阻塞患者(P=0.005)。接受 tPA 治疗的 ICA 阻塞患者中,大多数患者(100%)和接受安慰剂治疗的患者(77%)都没有获得良好的临床结局。本研究没有足够的效能来证明 tPA 对任何程度或严重程度的动脉阻塞患者有任何治疗获益。
动脉阻塞部位强烈预测结局。ICA 阻塞预后均较差,而 MCA 阻塞患者的良好结局与 tPA 治疗相关。